QNTM is trading at 5.8% up now at $3.56 after a sharp 7.18% drop on July 1. The stock has been under pressure from recent Lucid-MS / FDA uncertainty, but the latest clinical updates around the program have helped support sentiment.[6]
The broader market is also higher, with the S&P 500, Nasdaq, and Dow all up more than 0.5%, which may be adding tailwind to a small-cap biotech name like Quantum BioPharma.[1] No new company-specific announcement was identified in the July 2 pre-market window beyond that ongoing clinical-development backdrop.